Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Lophius Biosciences GmbH. (10/19/15). "Press Release: Lophius Biosciences Expands Management Team to Drive Marketing and Sales Activities". Regensburg.

Organisations Organisation Lophius Biosciences GmbH
  Organisation 2 Geneart AG
  Today Thermo Fisher Scientific Geneart GmbH
  Group Thermo Fisher (Group)
Products Product T-Track® CMV/EBV tests
  Product 2 synthetic gene
Persons Person Merkl, Bernd (Lophius 201510– Managing Director (Commercial Development) before Geneart 2005– BusDev Manager)
  Person 2 Phelps, Robert (Lophius Biosciences 201311– Director Business Operations before SuppreMol + PARI Pharma)
     


Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostics for functional assessment of pathogen/disease-reactive T cells, today announced the expansion of the management team.

Bernd Merkl, former site and product management leader of the GeneArt Centre of Excellence for Synthetic Biology within Thermo Fisher Scientific, has been appointed as co-CEO in order to drive the further development of the company in close collaboration with the current CEO Dr. Robert Phelps. As former Product Management Leader within Thermo Fisher Scientific and Chief Business Officer at GeneArt AG Bernd Merkl was responsible for the commercial development of the worldwide synthetic gene business, the magnetic bead sample prep business and the synthetic biology kit and service business. Bernd Merkl will focus on the commercial operations including all marketing and sales activities of Lophius Biosciences to further drive the commercial success of the company together with the team.

“We are pleased that we were able to find the right candidate to expand our management board in the marketing and sales area. Bernd Merkl and Dr. Robert Phelps will form together a strong team to continue and accelerate the successful development of Lophius Biosciences in the future” said Prof. Dr. Ralf Wagner, Chairman of the Supervisory Board. “With the growing number of products in the T Cell Tool space and the diagnostic area, like T-Track® CMV and the T-activated® ImmunoScan Cocktail, Lophius Biosciences supports the scientific and clinical community to significantly improve the standard of diagnosis and ultimately the treatment of diseases associated with immunosuppression. I am really happy to be part of this exciting opportunity and the team”, added Bernd Merkl, co-CEO at Lophius Biosciences. “I am very much looking forward to shift gears and bring Lophius to the next level of development together with Bernd”, Dr. Robert Phelps, co-CEO at Lophius Biosciences, commented.

   
Record changed: 2016-05-01

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Lophius Biosciences GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top